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Purpose: Currently, insufficient data exist to evaluate the relationship between an-
giographic late loss (LL) and long-term clinical outcome after drug-eluting stent 
(DES) implantation. In this study, we hypothesized that angiographic LL between 
0.3 and 0.6 mm correlate with favorable long-term clinical outcomes. Materials 
and Methods: Patients were enrolled in the present study if they had undergone 
both DES implantation in single coronary vessel and a subsequent follow-up an-
giogram (n=634). These individuals were then subdivided into three groups based 
on their relative angiographic LL: group I (angiographic LL <0.3 mm, n=378), 
group II (angiographic LL between 0.3 and 0.6 mm, n=124), and group III (angio-
graphic LL >0.6 mm, n=134). During a 5-year follow-up period, all subjects were 
tracked for critical events, defined as any cause of death or myocardial infarction, 
which were then compared among the three groups. Results: Mean follow-up du-
ration was 63.0±10.0 months. Critical events occurred in 25 subjects in group I 
(6.6%), 5 in group II (4.0%), and 17 in group III (12.7%), (p=0.020; group I vs. 
group II, p=0.293; group II vs. group III, p=0.013). In a subsequent multivariate 
logistic regression analysis, chronic renal failure [odds ratio (OR)=3.29, 95% con-
fidence interval (CI): 1.48-7.31, p=0.003] and long lesion length, defined as lesion 
length >28 mm (OR=1.88, 95% CI: 1.02-3.46, p=0.042) were independent predic-
tors of long-term critical events. Conclusion: This retrospective analysis fails to 
demonstrate that post-DES implantation angiographic LL between 0.3 and 0.6 mm 
is protective against future critical events.
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INTRODUCTION
Drug-eluting stents (DESs) have been widely used in percutaneous coronary inter-
ventions and they have reduced both restenosis rates and the need for repeat revas-
cularizations when compared with bare-metal stents.1,2 However, the safety and 
superiority of DESs has recently been called into question by data from several 
long-term monitory studies, in particular the incidence of stent thrombosis.3,4 Spe-
cifically, late stent thrombosis is believed to result from delayed coronary artery 
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met both the inclusion and exclusion criteria were enrolled 
and subsequently divided into three groups according to an-
giographic LL-individuals with angiographic LL <0.3 mm 
(group I; n=378), individuals with angiographic LL be-
tween 0.3 and 0.6 mm (group II; n=124), and individuals 
with angiographic LLs >0.6 mm (group III; n=134). In all 
cases, DES implantation was performed using conventional 
techniques without complication, with performing opera-
tor’s discretion determining the DES type employed. All 
patients were treated with 200 mg of aspirin and a loading 
dose (300 to 600 mg) of clopidogrel prior to coronary inter-
vention. Unfractionated heparin was also administered in 
an initial bolus of 100 IU/kg at this time, with additional 
boluses given throughout the procedure to achieve an acti-
vated clotting time of 250 to 300 seconds. Dual anti-platelet 
therapy (aspirin 100 mg/day and clopidogrel 75 mg/day) 
was given to all patients for at least 9 months after stent 
placement. 
Definitions and clinical outcomes
All clinical events were defined per those established by the 
Academic Research Consortium.9 All deaths were consid-
ered cardiac deaths unless a definite non-cardiac cause 
could be established. Myocardial infarctions were defined 
as clinical symptoms, electrocardiographic changes or ab-
normal imaging findings suggestive of myocardial infarc-
tion in combination with an increase in the serum creatine 
kinase MB or troponin-T/troponin-I to a level greater than 
the 99th percentile of the upper normal limit not related to 
an interventional procedure. Definite, probable, and possi-
ble stent thrombosis was defined per the recommendations 
of the Academic Research Consortium.9 Target vessel re-
vascularization was defined as either the percutaneous or 
surgical revascularization of the stented epicardial vessel. 
For the present study, the primary outcome was the inci-
dence of critical events-defined as any cause of death or 
myocardial infarction during the 5-year follow-up period-
which was then compared between the three subgroups.
Angiographic analysis
Quantitative coronary angiography analysis was performed 
using an offline quantitative coronary angiography system 
(CASS System II, Pie Medical Imaging, Nuenen, the Nether-
lands) both before and after stent placement and at the time 
of follow-up angiogram. Both the MLD of the DES-treated 
coronary lesions and the reference diameter were measured 
in the most severe view that was not foreshortened. 
healing secondary to excessive inhibition of neointimal for-
mation, with emerging data suggesting that the ratio of un-
covered stent struts to total stent struts is the best morpho-
metric predictor of late stent thrombosis.5 Furthermore, the 
development of optical coherence tomography (OCT) al-
lows for more accurate evaluation of the neointimal cover-
age of stent struts-widely regarded as the most powerful 
predictor of stent thrombosis based on several histopatho-
logic studies.6,7 However, given the cost and limited avail-
ability of this imaging modality, performing a follow-up 
OCT after every DES placement is currently not feasible in 
daily clinical practice. The angiographic late loss (LL)-de-
fined as the difference between the post-intervention mini-
mal lumen diameter (MLD) and follow-up MLD-is consid-
ered one of the most important endpoints used to evaluate 
DES efficacy,8 with our previous OCT study showing that 
angiographic LLs between 0.3 and 0.6 mm may represent 
an optimal midpoint between restenosis and stent thrombo-
sis.6 No clear clinical evidence to support these aforemen-
tioned angiographic cut-off values from previous study cur-
rently exists; therefore, the present study was designed to 
evaluate whether post-DES-placement angiographic LL be-
tween 0.3 mm and 0.6 mm correlate with a lower incidence 
of critical events.
MATERIALS AND METHODS
　　　
Study population
In total, 1062 patients were treated with DES for single cor-
onary vessel de novo lesions between March 2003 and De-
cember 2004, with only two types of DES used: sirolimus-
eluting (CypherTM, Cordis, Miami, FL, USA) and paclitaxel-
eluting stents (TaxusTM, Boston Scientific, Natick, MA, 
USA). Inclusion criteria for the present study included: an 
elective or emergent percutaneous coronary intervention, 
all those aged between 18 and 80 years, and follow-up of 
coronary angiogram 6-12 months after stent placement. Ex-
clusion criteria included cardiogenic shock, age younger 
than 18 or greater than 80 years, lack of an angiographic fol-
low-up study, and multi-vessel or multi-lesion stent place-
ments. Angiographic follow-up studies were generally per-
formed for the following reasons: evidence suggesting 
myocardial ischemia upon stress test, clinical evidence of 
acute coronary syndrome, or planned follow-up angiogra-
phy for other study protocols. Using the percutaneous coro-
nary intervention database at our institute, 636 patients who 
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cal events were chronic renal failure [odds ratio (OR)=3.29; 
95% confidence interval (CI): 1.48-7.31; p=0.003] and long 
lesion length (lesion length >28 mm; OR=1.88; 95% CI: 
1.02-3.46; p=0.042) (Table 4). The incidence of clinical 
events according to the longitudinal follow-up time using 
Kaplan-Meier curves can be seen in Fig. 1.
DISCUSSION
The degree of LL was closely related to in-stent restenosis by 
the proliferation of neointimal tissue. One previous angio-
graphic study of 1011 lesions treated with sirolimus-eluting 
stents reported that in-stent LL-an angiographic surrogate for 
neointimal hyperplasia-is positively correlated with clinical 
restenosis, and therefore potentially useful for discriminating 
between new DESs because the binary restenosis rates are 
anticipated to be low.10 Another recent meta-regression anal-
ysis of 15846 patients from 29 randomized clinical trials also 
reported that LL is a strong predictor of binary angiographic 
restenosis and target vessel revascularization.11 Accordingly, 
it appears that the new DES platforms need to achieve as low 
LL as possible to be safe and certainly well below the 0.5 
mm in order to ensure the rare need for target vessel revascu-
larization.11 However, reducing post-DES-placement LL to 
decrease the need for target vessel revascularization may par-
adoxically increase the probability of uncovered stent struts, 
as smaller LL values correlate with higher percentages of un-
covered stent struts. Recently, the safety profile of DESs has 
been called into question, primarily due to their potential as-
sociation with stent thrombosis and subsequent catastrophic 
outcomes, with uncovered stent struts believed to represent 
the most significant predictor of stent thrombosis. Therefore, 
while stent strut neointimal coverage may exert a protective 
role against stent thrombosis, exaggerated neointimal prolif-
eration, which directly results in larger LL value, increases 
the likelihood of target vessel revascularization. Given this 
paradox, the presence of minimal neoinitmal stent strut cov-
erage (e.g., coverage that is neither absent nor profuse) may 
optimally balance the risk of restenosis with that of stent 
thrombosis. In a previous study,6 we proposed 2 angiograph-
ic LL cut-off values for predicting the percentage of uncov-
ered struts in DES-treated lesions. Lesions with an angio-
graphic LL <0.3 mm, in which neointimal hyperplasia was 
suppressed, were associated with a lower risk of restenosis, 
however, they were more likely to contain uncovered struts, 
and carry a greater risk of stent thrombosis. Conversely, le-
Statistical analyses 
All statistical analyses were performed using the Statistical 
Analysis System software (SAS; v9.1.3., SAS Institute Inc., 
Cary, NC, USA), with all data expressed as frequencies as 
mean±SD. Categorical data were compared by either chi-
square tests or Fisher’s exact test. Continuous data were 
presented as mean±standard deviation, and compared using 
the Student’s t-test. Comparisons between all three groups 
were performed via an analysis of variance using the Bon-
ferroni correction for post hoc analysis. In cases where the 
distributions were skewed, a non-parametric test was used. 
We estimated the cumulative event rate using the Kaplan-
Meier method. To identify independent predictors for criti-
cal events, a Cox proportional hazards regression analysis 
was used to identify possible significant associations be-
tween the events and a number of independent variables, 
then the variables with a univariate analysis p-value of <0.1 
and significant clinical variables (acute coronary syndrome 
and diabetes mellitus) were entered into the final multivari-
ate logistic regression analysis. In all cases, a p value of 
<0.05 was considered statistically significant.
 
RESULTS
 
Baseline clinical and angiographic characteristics among 
the three groups are shown in Table 1. Paclitaxel-eluting 
stents were used more frequently in group III. Post-inter-
vention MLD was also significantly greater in group III. All 
comparisons of long-term clinical events between the three 
groups are shown in Table 2. Mean follow-up duration for 
all subjects was 63.0±10.0 months (63.0±9.9 for group I, 
64.2±9.2 for group II, and 62.8±10.7 for group III; p=0.458). 
Death or myocardial infarction occurred in 25 patients in 
group I (6.6%), 5 patients in group II (4.0%), and 17 patients 
in group III (12.7%), with (p=0.020; group I vs. group II, 
p=0.293; group II vs. group III, p=0.013). Target vessel re-
vascularization was performed in 38 individuals in group I 
(10.1%), 17 individuals in group II (13.7%), and 50 indi-
viduals in group III (37.3%), with p<0.001. Stent thrombo-
sis occurred in 14 subjects in group I (3.7%), 4 subjects in 
group II (3.2%), and 8 subjects in group III (6.0%), with 
p=0.452. Baseline clinical and angiographic characteristics 
between patients who did and did not experience long-term 
critical events during the 5-year follow-up period are listed 
in Table 3. In the subsequent multivariate logistic regres-
sion analysis, the independent predictors of long term criti-
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Table 1. Baseline Clinical and Angiographic Characteristic among the Three Groups
0.3 mm<LL 
(n=378)
0.3 mm≤LL 
≤0.6 mm (n=124)
LL>0.6 mm 
(n=134)
p value
Clinical variable
    Age (yrs) 59.3±9.6 61.1±10.5 60.6±9.9 0.144
    Male [n (%)]  265 (70.1) 89 (71.8)   90 (67.2) 0.709
    Diabetes mellitus [n (%)]  108 (28.6) 44 (35.5)     51 (38.1)* 0.082
    Hypertension [n (%)]  223 (59.0) 78 (62.9)   83 (61.9) 0.681
    Hypercholesterolemia [n (%)]    91 (24.1) 34 (27.4)   28 (20.9) 0.472
    Current smoker [n (%)]  122 (32.3) 40 (32.3)   44 (32.8) 0.992
    Acute coronary syndrome [n (%)]  186 (49.2) 59 (47.6)     80 (59.7)* 0.077
    Acute myocardial infarction [n (%)]    60 (15.9) 14 (11.3)   24 (17.9) 0.314
    Primary PCI [n (%)]  12 (3.2) 2 (1.6)   3 (2.2) 0.607
    Chronic renal failure [n (%)]  20 (5.3) 8 (6.5) 12 (9.0) 0.323
    Congestive heart failure [n (%)]  20 (5.3) 3 (2.4)   4 (3.0) 0.278
Angiographic variable
    Target vessel [n (%)]
        Left anterior descending artery  240 (63.5) 83 (66.9)   78 (58.2) 0.336
        Left circumflex artery    74 (19.6) 17 (13.7)   26 (19.4) 0.324
        Right coronary artery    64 (16.9) 24 (19.4)   30 (22.4) 0.324
    Extent of diseased vessels [n (%)]
        1-vessel  121 (32.5) 31 (25.6)     44 (33.31) 0.321
        2-vessel  134 (36.0) 58 (47.9)   49 (36.8) 0.059
        3-vessel 1 17 (31.5) 32 (26.4)   40 (30.1) 0.581
    Lesion length (mm) 22.0±7.6 23.6±8.9 20.8±7.6 0.018
    Lesion length >28 mm [n (%)]    83 (22.3) 32 (26.2)   24 (18.0) 0.289
    Stent diameter (mm)     3.0±0.34   3.0±0.34   3.1±0.32 0.038
    Stent length (mm) 23.8±9.8 23.3±12.6 22.9±9.6 0.632
    Stent implanted [n (%)] <0.001
        Sirolimus-eluting stent  295 (75.0) 86 (69.4)   77 (57.5)
        Paclitaxel-eluting stent    83 (22.0) 38 (30.6)   57 (42.5)
    Follow-up angiogram after index PCI (days) 270±77 261±60 283±72 0.661
    Proportion of scheduled follow-up angiogram [n (%)]  366 (96.8) 119 (96.0) 126 (94.0) 0.359
Quantitative coronary angiographic analysis
    Reference vessel size (mm)   2.76±0.51 2.74±0.60 2.77±0.60 0.953
    Pre-intervention MLD (mm)   0.69±0.45 0.70±0.40 0.76±0.51 0.359
    Post-intervention MLD (mm)   2.76±0.44 2.86±0.43 3.00±0.44 <0.001
    Follow-up MLD (mm)   2.81±0.47 2.43±0.43 1.59±0.85 <0.001
    LL (mm)  -0.05±0.38 0.42±0.09 1.41±0.76 <0.001
LL, late loss; MLD, minimal lumen diameter; PCI, percutaneous coronary intervention.
*p<0.05 compared with 0.3 mm <LL group.
Table 2. Comparison of Long-Term Clinical Events between the Three Groups
0.3 mm<LL 
(n=378)
0.3 mm≤LL 
≤0.6 mm (n=124)
LL>0.6 mm 
(n=134)
p value
Death [n (%)] 19 (5.0) 3 (2.4)   7 (5.2) 0.443
Myocardial infarction [n (%)]   8 (2.1) 4 (3.2) 11 (8.2) 0.005
Death+myocardial infarction [n (%)] 25 (6.6) 5 (4.0)   17 (12.7) 0.020
Target vessel revascularization [n (%)]   38 (10.1) 17 (13.7)   50 (37.3) <0.001
Stent thrombosis [n (%)] 14 (3.7) 4 (3.2)   8 (6.0) 0.452
LL, late loss.
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Table 3. Baseline Clinical and Angiographic Characteristics in Patients Who Did and Did Not Experience Long-Term Critical 
Events
Presence of critical events 
(n=47)
Absence of critical events 
(n=589)
p value
Clinical variable
    Age (yrs)  62.8±11.1 59.7±9.8 0.041
    Male [n (%)] 39 (83.0) 405 (68.8) 0.041
    Diabetes mellitus [n (%)] 20 (42.6) 183 (31.1) 0.104
    Hypertension [n (%)] 30 (63.8) 354 (60.1) 0.615
    Hypercholesterolemia [n (%)]   6 (15.0) 147 (29.5) 0.050
    Current smoker [n (%)] 19 (40.4)   18 (31.7) 0.221
    Acute coronary syndrome [n (%)] 29 (61.7) 296 (50.3) 0.131
    Chronic renal failure [n (%)] 10 (21.3) 30 (5.1) <0.001
    Congestive heart failure [n (%)] 2 (4.3) 25 (4.2) 0.997
Angiographic variable
    Target vessel [n (%)] 0.558
        Left anterior descending artery 26 (55.3) 295 (50.1)
        Left circumflex artery  15 (31.9) 182 (30.9)
        Right coronary artery   6 (12.8) 112 (19.0)
    Extent of diseased vessels [n (%)] 0.281
        1-vessel 17 (36.2) 179 (30.9)
        2-vessel 13 (27.7) 228 (39.4)
        3-vessel 17 (36.2) 172 (29.7)
    Lesion length (mm) 23.4±8.7 21.9±7.9 0.233
    Lesion length >28 mm [n (%)] 16 (34.0) 123 (21.2) 0.041
    Stent diameter (mm)   2.95±0.32 3.01±0.34 0.257
    Stent length (mm)   23.6±12.1 23.5±10.2 0.962
    Stent implanted [n (%)] 0.959
        Sirolimus-eluting stent 34 (72.3) 424 (72.0)
        Paclitaxel-eluting stent 13 (27.7) 165 (28.0)
Quantitative coronary angiographic analysis
    Reference vessel size (mm)   2.73±0.56 2.76±0.55 0.788
    Pre-intervention MLD (mm)   0.64±0.39 0.71±0.46 0.331
    Post-intervention MLD (mm)   2.73±0.52 2.84±0.44 0.114
    Follow-up MLD (mm)   2.01±1.13 2.52±0.69 0.004
    Late loss (mm)   0.72±1.22 0.32±0.65 0.032
MLD, minimal lumen diameter.
Table 4. Predictors of Critical Events during the 5-Year Follow-Up Period
Univariate Multivariate
OR (95% CI) p value OR (95% CI) p value
<0.3 vs. 0.3≤LL≤0.6 1.66 (0.64-4.34)  0.301 1.86 (0.71-4.87) 0.209
>0.6 vs. 0.3≤LL≤0.6 3.32 (1.23-9.00)  0.018 3.17 (1.15-8.71) 0.026
Age, per yr 1.03 (1.00-1.06)  0.040 1.02 (1.00-1.06) 0.110
Female gender 0.46 (0.22-0.99)  0.048 0.52 (0.23-1.14) 0.102
Hypercholesterolemia 0.44 (0.18-1.04)  0.060 0.55 (0.23-1.33) 0.185
Diabetes mellitus 1.60 (0.90-2.86)  0.110 1.29 (0.69-2.41) 0.422
Chronic renal failure 4.52 (2.25-9.08) <0.001 3.29 (1.48-7.31) 0.003
Acute coronary syndrome 1.56 (0.88-2.85)  0.128 1.54 (0.85-2.79) 0.159
Long lesion (>28 mm) 1.89 (1.04-3.46)  0.038 1.88 (1.02-3.46) 0.042
OR, odds ratio; CI, confidence interval; LL, late loss.
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sions with an angiographic LL >0.6 mm had significantly 
fewer uncovered struts, a greater risk of restenosis, and were 
more likely to require target-lesion revascularization; howev-
er, they carried a lower risk of stent thrombosis. Based on the 
previous hypothesis-generation study, we proposed the safety 
margins of post-DES-placement angiographic LL between 
0.3 mm and 0.6 mm in order to balance the risks of resteno-
sis and stent thrombosis.6
In the present study, although the incidence of death or 
myocardial infarction (including stent thrombosis) was low-
est in group II, statistical significance was not reached when 
compared with group I. We believe that several possible 
factors may explain these results. First, this study is retro-
spective and non-randomized; therefore, it is intrinsically 
vulnerable to selection bias and other unobserved confound-
ing factors. Second, the incidence of major adverse clinical 
events during the 5-year follow-up was low to achieve stat-
ically significant differences. Third, the number of enrolled 
patients was relatively small. Lastly, neointimal growth may 
have been delayed after DES implantation, as several previ-
ous animal studies suggest that, when compared with bare-
metal stents, late neointimal growth may occur despite a 
marked early suppression of neointimal formation within 
DESs.12,13 Furthermore, neoatherosclerosis may also devel-
op earlier in DES-treated lesions when compared to bare-
metal stent-treated lesions. Data now demonstrate that al-
though atherosclerotic changes often do not appear until 2 
years after bare-metal stent implantation and remain a rare 
finding at 4 years, atherosclerotic changes-including foamy 
macrophage infiltration and early necrotic core formation-
were observed in more than 40% of patients 9 months after 
sirolimus-eluting stent implantation.14 A more recent autop-
sy study also reported that the incidence of neointimal ath-
erosclerotic change was significantly greater in DES-treated 
lesions (31%) when compared to bare-metal stent-treated le-
sions (16%).15 Another recent OCT study showed that rup-
ture of lipid-laden neointima inside DES may be associated 
with late stent thrombosis after DES implantation.16 Ac-
cordingly, it is unlikely that LL is the only factor affecting 
the dynamic process of neoatherosclerosis within DES-treat-
ed lesions, and the causes of stent thrombosis and other car-
diac events. The results presented here correlate well with 
previous studies, which demonstrated a negative relation-
ship between LL and stent thrombosis.17,18 
In conclusion, our hypothesis that an angiographic LL be-
tween 0.3 and 0.6 mm may correlate with a lower incidence 
of critical events after DES placement was not supported by 
Fig. 1. Using Kaplan-Meier curves, the incidence of clinical events of three 
groups according to angiographic late loss (<0.3 mm, between 0.3 and 0.6 
mm and >0.6 mm) are shown. (A) Death or myocardial infarction free sur-
vival rate. (B) Target vessel revascularization free survival rate. (C) Stent 
thrombosis free survival rate.
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